European Society of Anaesthesiology.

E xsanguination is responsible for 30% to 40% of trauma-related deaths. 1,2 Most of these fatalities occur in the prehospital setting. According to standard coagulation tests (SCTs), one quarter to one third of trauma patients present with coagulopathy on admission to the emergency department. 3Y5 The presence of coagulopathy increases the risk for poor outcomes, thus resulting in threefold to fourfold higher mortality rates. 3,5 Coagulopathic patients are at risk of exsanguination. It is assumed that up to 20% of these fatalities are potentially preventable by early hemostatic intervention. 6 Therefore, timely and reliable identification of the underlying cause of bleeding is paramount to improve survival.Despite remarkable advances in knowledge, the etiology of trauma-induced coagulopathy (TIC) is still not fully understood. Recent concepts suggest an ''endogenous'' TIC primarily driven by shock-associated hypoperfusion in combination with tissue trauma, which activates the protein C pathway, resulting in anticoagulation, hypofibrinogenemia, hyperfibrinolysis (HF), and platelet dysfunction. 7,8 In addition, ''exogenous'' factors such as consumption of coagulation proteins, in particular fibrinogen, and dilution of the remaining coagulation factors, accompanied by other potentiating effects, such as acidosis, hypothermia, and electrolyte disturbance, further contribute to TIC. 9 Importantly, TIC is not uniform but varies with pattern of injury and in type during the course of treatment, underscoring the potential importance of point-of-care (POC) testing that can rapidly provide information on an actual individual patient's coagulation status. 10 Conventional plasma-based coagulation testing, such as prothrombin time (PT) or international normalized ratio (INR), and activated partial thromboplastin time (aPTT) fail to fully assess the clotting process. SCTs were designed to evaluate anticoagulation therapy rather than coagulopathy in major trauma. 11 In fact, none of the conventional coagulation tests was developed to predict bleeding or to guide coagulation in the surgical setting. 11Y14 Moreover, a substantial amount of precious time transpires before the results of standard coagulation assessments become available, with a median turnaround time for these tests to be completed at a central laboratory ranging from 78 minutes to 88 minutes. 15,16 Viscoelastic tests (VETs), most commonly thrombelastography (TEG, Haemoscope-Haemonetics, Niles, IL) and rotational thromboelastometry (TEM, Tem Systems Inc., Durham, NC), provide a valuable alternative or an adjunct to SCT in the setting of bleeding in the emergency department. VETs yield rapid, POC assessment of whole-blood coagulation in a variety of conditions in which conventional testing may not be sensitive. 12,15,17,18 Unlike SCT, VETs provide a rapid and dynamic bedside assessment of the initiation and kinetics of clot formation, maximum clot firmness (MCF), and clot breakdown. 12,17,18 VETs can characterize the range of acute coagulopathies present in patient...

Glanzmann's thrombasthenia is a rare, inherited disease, which consists in abnormality of the glycoprotein IIa/IIIb genes that causes impaired platelet function. Glanzmann's thrombasthenia patients show prolongation of bleeding time and may experience life-threatening hemorrhage after surgery. We present a case of a young woman having Glanzmann's thrombasthenia, who underwent gynecological operation for ovarian cyst. Perioperative monitoring included thromboelastometry with ROTEM and impedance aggregometry with ROTEMplatelet. In this case, despite acceptable ROTEM results after platelet transfusion, ROTEMplatelet was more indicative of hemostatic impairment and reflected the bleeding occurred in the postoperative period. When treating patients with congenital or acquired platelet dysfunction, some intrinsic limits of thromboelastometry to assess platelet function may be overcome with the combined use of a point-of-care device that measures platelet aggregation.